Although numerous other biomarkers (e.g., IL-18, L-FABP, cystatin C, suPAR) have been investigated for AKI prediction, they were not included in this review due to inconsistent validation, lack of widespread clinical availability, or limited studies in ICU populations. This evidence concerns the gene IL18 and acute kidney injury.